58 related articles for article (PubMed ID: 16127622)
1. Iloperidone (Hoechst Marion Roussel Inc).
Hesselink JM
IDrugs; 1999 Jun; 2(6):584-90. PubMed ID: 16127622
[TBL] [Abstract][Full Text] [Related]
2. Iloperidone (Novartis).
Hesselink JM
IDrugs; 2002 Jan; 5(1):84-90. PubMed ID: 12861482
[TBL] [Abstract][Full Text] [Related]
3. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
4. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
[TBL] [Abstract][Full Text] [Related]
5. Transgenic antithrombin III (Genzyme).
Yeung PK
IDrugs; 2000 Jun; 3(6):669-73. PubMed ID: 16096931
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
Potkin SG; Litman RE; Torres R; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
[TBL] [Abstract][Full Text] [Related]
8. Pralnacasan (vertex pharmaceuticals).
Siegmund B; Zeitz M
IDrugs; 2003 Feb; 6(2):154-8. PubMed ID: 12789619
[TBL] [Abstract][Full Text] [Related]
9. CX-516 (Cortex Pharmaceuticals Inc).
Danysz W
IDrugs; 1999 Aug; 2(8):814-22. PubMed ID: 16127658
[TBL] [Abstract][Full Text] [Related]
10. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.
Lavedan C; Licamele L; Volpi S; Hamilton J; Heaton C; Mack K; Lannan R; Thompson A; Wolfgang CD; Polymeropoulos MH
Mol Psychiatry; 2009 Aug; 14(8):804-19. PubMed ID: 18521090
[TBL] [Abstract][Full Text] [Related]
11. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats.
Barr AM; Powell SB; Markou A; Geyer MA
Neuropharmacology; 2006 Sep; 51(3):457-65. PubMed ID: 16762376
[TBL] [Abstract][Full Text] [Related]
12. ABX-CBL (Abgenix Inc).
von Appen K
IDrugs; 1999 Jan; 2(1):65-8. PubMed ID: 16180173
[TBL] [Abstract][Full Text] [Related]
13. RU-486: Hoechst-Roussel (US), Hoechst AG, Roussel Uclaf SA, and Hoechst-Roussel Pharmaceuticals Inc.
JAMA; 1991 Feb; 265(7):868. PubMed ID: 1992181
[No Abstract] [Full Text] [Related]
14. Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
[TBL] [Abstract][Full Text] [Related]
15. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
Meltzer HY; Huang M
Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
17. A curious stopping rule from Hoechst Marion Roussel.
Lancet; 1997 Jul; 350(9072):155. PubMed ID: 9250175
[No Abstract] [Full Text] [Related]
18. A review of new atypical antipsychotic launches in the United States.
Ventimiglia J; Kalali AH; Citrome L
Psychiatry (Edgmont); 2010 Dec; 7(12):13-5. PubMed ID: 21274390
[TBL] [Abstract][Full Text] [Related]
19. DHEA (Leland Stanford Junior University).
Norman P
IDrugs; 1999 Jan; 2(1):59-64. PubMed ID: 16180172
[TBL] [Abstract][Full Text] [Related]
20. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
Weiden PJ
J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
